Scientific publication

EP0031 poster presented at ASCO 2024

Phase 1 study data for EP0031/A400, presented at ASCO 2024 Download larger version About Ellipses Pharma Limited Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection with an uninterrupted funding [...]

Ellipses Pharma: How to develop cancer drugs faster

Next generation treatments for non-small cell lung cancer

Unlocking the Potential of RET-Targeted Cancer Therapies

Unlocking the Potential of RET-Targeted Cancer Therapies Simple Summary: Since the discovery of the RET gene in the early 1980s, multiple treatments have been developed that can inhibit abnormal RET signaling. The first treatments were repurposed multikinase inhibitors, however, their low selectivity for RET led to unacceptable off-target toxicities and sub-optimal exposure in patients. More [...]

A Phase 1 Study of KL590586 (A400/EP0031)

A Phase 1 Study of KL590586 (A400/EP0031) - A next-generation selective RET inhibitor in patients with RET-altered solid tumours Download PDF About Ellipses Pharma Limited Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to [...]

EP0031 poster presented at AACR-NCI-EORTC Conference 2023

A modular, open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies Download larger version About Ellipses Pharma Limited Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through [...]

EP0062/vosilasarm abstract presented at AACR 2023

EP0042, a Dual FLT3 and Aurora Kinase Inhibitor